



DIASORIN AND LABCORP EXTEND STRATEGIC BUSINESS RELATIONSHIP.

Saluggia (Italy) May 11, 2011- DiaSorin Group, a worldwide leader in the in vitro diagnostic market, and Laboratory Corporation of America Holdings (LabCorp®), have signed a five year supply agreement. DiaSorin will provide LabCorp with its new high-throughput LIAISON XL analyzer, an FDA-approved 25 OH Vitamin D assay, and a range of infectious disease assays. This agreement further demonstrates DiaSorin's commitment to be a reliable, long-term supplier to large commercial laboratories.

In the United States, DiaSorin plays the "pure specialist" strategy, offering a large number of specialty tests in the areas of infectious diseases and bone and mineral related diseases. The US market represents a primary focus for DiaSorin, thanks to the excellent growth there in the last few years accounting for almost 35% of the Group revenues.

Mr. Carlo Rosa, DiaSorin CEO, welcomed the agreement saying: "We are proud to announce this agreement that will enable us to remain LabCorp's strategic partner. This agreement will contribute significantly to the stability of our US network and to the DiaSorin Group's future growth."



About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Kyalami (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.DiaSorin.com

Contacts:

Investor Relations Director

Laura Villa

DiaSorin S.p.A.

laura.villa@DiaSorin.it

+39 0296474567

+39 3481511542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 3356555651

Bruno Caprioli

caprioli@mailander.it